Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Panelists discuss how payers seek good return on investment when evaluating expensive gene therapies, creating potential friction when innovative treatments come at significant costs, requiring ...